Logo

OSRHW

OSR Holdings, Inc.

OSRHW

OSR Holdings, Inc. • NASDAQ
$0.06 ▼ -0.62% (-0.00)
Market Cap $13.96 M
52w High $0.06
52w Low $0.04
Dividend Yield 0%
P/E 0
Volume 8.91K
Outstanding Shares 218.51M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $627.747K ▼ $4.065M ▼ $-3.195M ▼ -508.943% ▼ $-0.1 ▼ $-2.059M ▲
Q2-2025 $1.136M ▲ $5.262M ▲ $331.414K ▲ 29.186% ▲ $0.02 ▲ $-2.837M ▲
Q1-2025 $761.272K ▲ $3.087M ▲ $-11.393M ▼ -1.497K% ▼ $-1.04 ▼ $-9.103M ▼
Q4-2024 $-2.395M ▼ $2.144M ▼ $-2.022M ▲ 84.423% ▲ $0.47 ▲ $-1.907M ▼
Q3-2024 $849.802K $3.865M $-3.462M -407.342% $-0.057 $-757.154K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.177M ▲ $177.29M ▼ $43.132M ▼ $81.945M ▼
Q2-2025 $1.584M ▼ $185.415M ▲ $46.262M ▲ $83.702M ▲
Q1-2025 $1.596M ▲ $174.55M ▲ $42.268M ▲ $75.76M ▲
Q4-2024 $66.135K ▲ $2.303M ▼ $8.789M ▲ $-6.486M ▼
Q3-2024 $12.236K $20.926M $6.011M $14.915M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.127M ▼ $-2.711M ▼ $-726.632K ▼ $4.116M ▲ $592.903K ▲ $0 ▲
Q2-2025 $331.414K ▲ $-482.607K ▼ $-528.424K ▼ $891.482K ▲ $-11.291K ▼ $-485.29K ▼
Q1-2025 $-11.393M ▼ $-64.069K ▲ $1.186M ▼ $149.381K ▲ $1.254M ▲ $-64.069K ▲
Q4-2024 $-2.022M ▼ $-502.905K ▼ $18.973M ▲ $-18.416M ▼ $53.899K ▲ $-502.909K ▼
Q3-2024 $-230.961K $-226.88K $-150K $270K $-106.88K $-226.88K

Five-Year Company Overview

Income Statement

Income Statement OSR Holdings is still in a very early, pre-commercial stage. The company has essentially no reported revenue yet, which is typical for a young biotech focused on developing therapies rather than selling approved products. Profitability is not in sight at this point: earnings per share recently swung from a small profit to a notable loss, suggesting higher spending, likely on R&D, deals, and corporate build-out. Overall, the income statement reflects a company still firmly in the investment phase of its lifecycle rather than one generating ongoing operating profits.

Balance Sheet

Balance Sheet The balance sheet looks very light, with only modest levels of total assets reported and no meaningful cash balance shown in the data provided. Debt popped up recently, while shareholder equity turned slightly negative, which is a sign of financial strain and dependence on future funding, partnerships, or equity raises. In practical terms, OSR appears thinly capitalized and highly sensitive to funding access, deal execution, and market conditions. This is not unusual for small biotech platforms, but it does raise the importance of careful cash and risk management.

Cash Flow

Cash Flow There is no meaningful operating or free cash flow data reported, which fits a business that has yet to generate revenue and is likely burning cash on development activities behind the scenes. Without visibility on cash burn and funding runway, it is hard to judge how long current resources will last or when the company might need additional capital. For a company like OSR, future partnership payments, milestone receipts, or new financing will be critical to support ongoing trials and acquisitions.

Competitive Edge

Competitive Edge OSR’s competitive position comes from a portfolio of differentiated technologies rather than from current market share. It is building three main pillars: oral cancer immunotherapies, advanced biologics for degenerative diseases, and noninvasive glucose monitoring, plus an existing Korean medical device distribution arm. The technologies aim to solve difficult clinical problems with more patient-friendly or more powerful approaches than many existing options. However, OSR is competing in crowded, well-funded areas—cancer immunotherapy, regenerative medicine, and diabetes devices—against very large global players. Its edge lies in its proprietary platforms, patents, and “hub-and-spoke” structure, but its position is still emerging and unproven at commercial scale.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of OSR. The company controls a first-in-class oral cancer vaccine platform, AI-designed biologics that seek to regenerate tissue rather than only ease symptoms, and a truly needle-free glucose monitoring technology using light-based sensing. Several programs already have encouraging early data or clinical experience, and there is a growing patent estate supporting them. That said, most assets are still in early or mid development, with key clinical trials and regulatory steps still ahead. Execution risk is high: success will depend on translating promising science into robust late-stage data, approvals, and real-world adoption, and on managing multiple complex programs at once.

Summary

Overall, OSR Holdings looks like a high-innovation, high-risk biotech platform at a very early commercial stage. Financially, it is still pre-revenue, thinly capitalized, and reliant on future funding events and partnerships. Strategically, it is trying to build value through several ambitious platforms across cancer, degenerative disease, and diabetes care, complemented by a revenue-generating distribution business in Korea. The long-term upside depends on successful clinical results, regulatory progress, and deal-making—any of which could significantly reshape its financial profile—but uncertainty remains high until more clinical, commercial, and funding milestones are clearly delivered.